Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-06-14
2011-06-14
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S176000, C514S177000, C514S178000, C514S179000, C514S180000, C514S181000, C514S182000, C540S106000, C540S107000, C540S108000, C540S109000, C540S110000, C540S111000, C540S112000, C540S114000, C540S116000, C540S036000, C552S600000
Reexamination Certificate
active
07960367
ABSTRACT:
Steroid compounds processing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.
REFERENCES:
patent: 5439900 (1995-08-01), Bukusoglu et al.
patent: 2002/0072509 (2002-06-01), Stein et al.
patent: WO 96/15782 (1996-05-01), None
patent: WO 98/50042 (1998-11-01), None
patent: WO 98/50410 (1998-11-01), None
patent: WO 98/50411 (1998-11-01), None
patent: WO 9850042 (1998-11-01), None
patent: WO 9850410 (1998-11-01), None
patent: WO 9850411 (1998-11-01), None
patent: WO 99/45931 (1999-09-01), None
patent: WO 9945931 (1999-09-01), None
patent: WO 00/21977 (2000-04-01), None
patent: WO 0021977 (2000-04-01), None
Hamilton, Therapeutic Potential of Steroids for CNS Disorders, 2001, Ashley Publications, vol. 11, No. 10, pp. 1523-1531.
Lance et al., Indentification of a series of C21O2 pregnanes from fecal extracts of a pregnant black rhinoceros, Steroids, vol. 66, 2001, pp. 875-881.
Dorwald, Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Wiley VCH, 2005, IX Preface.
International Search Report of corresponding EP application mailed Apr. 7, 2006, EP Application No. 02 793 723.4-1216, 4 pages.
Akhondzadeh, S., et al. “Potentiation of Muscimol-Induced Long-Term Depression by Benzodiazepines and Preention or Reversal by Pregnenolone Sulfate” Pharm. Res. 38(6):441-447 (1998).
Chen, S.W. et al. The Hyperphagic Effect of 3α-Hydroxylated Pregnane Steroids in Male Rats, Pharm. Bioch. & Behavior 53(4):777-782 (1996).
Prince, R.J. et al., “Diffential Antagonism by Epipregnanolone of Alphaxalone and Pregnanolone Potentiation of [3H]Flunitrazepam Binding Suggests More Than the One Class of Binding Site for Steroids at GABAAReceptors”, Neuropharmacology 32(1):59-63(1993).
Reddy, D. S., “Sigma (σ1)receptor mediated anti-depressant-like efects of neurosteroids in the Porsolt forced swim test” NeuroReport 9, 3069-3073 (1998).
Akhondzadeh, S. et al. (1998) “Potentiation of Muscimo1-Induced Long-Term Depression by Benzodiazepines and Prevention or Reversal by Pregnenolone Sulfate”Pharmacological Research38(6): 441-447.
Doodipala, Samba Reddy et al. (1998) “Sigma (o1,) Receptor Mediated Anidepressant-Like Effects of Neurosteroids in the Porsolt Forced Swin Test”NueroReport9: 3069-3073.
Prince R. J. et al. (1993) “Differential Antagonism by Epipregnanolone of Alphaxalone and Pregnanolone Potentiation of (3H) Flunitrazepam Binding Suggests More Than One Class of Binding Site for Steroids at Gaba a Receptors”Neuropharmacology32(1): 59-63.
International Search Report mailed on May 6, 2003, for PCT patent Application No. PCT/SE02/02423 filed on Dec. 20, 2002, 4 pages.
Prince, R.J. et al. (1992). “5β-Pregnan-3β-ol-20-one a specific antagonist at the neurosteroid site of the GABAAreceptor-complex,”Neuroscience Letters135:273-275.
Office Action received for Japanese Patent Application No. 2003-559519, mailed on Mar. 2, 2010, 3 pages of Office Action and 5 pages of English Translation.
Clark et al., “Substrate specificity of cholesterol oxidase”, Clinical Chemistry, vol. 26, No. 5, 1980, p. 678.
Kokate et al., “Anticonvulsant activity of Neurosteroids: Correlation with γ-Aminobutyric Acid-Evoked Chloride Current Potentiation”, The Journal of Pharmacology and Experimental Therapeutics, vol. 270, No. 3, 1994, pp. 1223-1229.
Nagata et al., “Stereospecific total synthesis of dl-5α-preganan-3β-ol-20-one”, Tetrahedron Letters, vol. 4, No. 14, 1963, pp. 865-868.
Backstrom Torbjorn
Johansson Inga-Maj
Lundgren Per
Wang Ming-De
Holloman Nannette
Krass Frederick
Morrison & Foerster / LLP
Umecrine AB
LandOfFree
Pregnane steroids and their use in the treatment of CNS... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pregnane steroids and their use in the treatment of CNS..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pregnane steroids and their use in the treatment of CNS... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726860